每经记者｜陈星 实习生 范芊芊 每经编辑｜文多 4月10日，2021全国疫苗与健康大会在成都召开。国家卫生健康委医药卫生科技发展研究中心主任、国 务院联防联控机制科研攻关组疫苗研发工作组组长郑忠伟参与了"由新冠疫苗看中国疫苗创新"为主题的 圆桌访谈。他表示，对于中国疫苗研发，在坚定自信的同时，也要了解不足。 "从此次新冠疫苗研发来看，我们所有的中国人既要有中国自信，也要有中国冷静。"他说。 封面图片来源：摄图网 他指出，在生物医药领域，我国有一些国家优势，包括体制、组织、文化优势；而不足则体现在基础研 究、载体平台、组织研发等方面，尤其在国际临床项目上与国外差距明显。 那么国际临床项目上的差距如何补足？他说，"十四五"期间，国家大概要投入40亿元左右用于推进病原 学和免疫技术体系方面的研发项目。其次，重大传染病专项培养技术也会在"十四五"期间尽早投入。另 外，目前一些疫苗方面的突破得益于企业的储备。 ...

转自：新华财经 11月21日晚，辽宁成大（600739.SH）发布公告，经公司董事会审议，同意新疆宝明矿业有限公司（以 下简称"新疆宝明"）长期停产。公司不再向新疆宝明追加大额现金投入，将继续努力推动新疆宝明引入 战略投资者解决其自身的资金和发展问题。未来，公司将以稳健的金融资产为基础，主要聚焦生物医药 等核心产业；同时，结合国家产业政策，积极探索新质生产力相关产业投资机会，实现新的高质量发 展。 据市场相关人士分析，新疆宝明此次长期停产属于"止血"动作，是公司换届后新管理层实施战略转向的 重要信号。2025年，在新管理团队经营下，公司各业务板块获得了明显的边际改善，朝着提质向新的目 标不断迈进。 优化融资：合理运用多种融资工具，推动资产负债结构更趋稳健 今年2月，辽宁成大完成新一届董事会选举及新一届高管团队聘任。新任董事长徐飚先生自2020年开始 便担任公司董事，来自广东民营投资股份有限公司（以下简称"粤民投"），具有丰富的产业与资本资 源；新任总裁张善伟先生自2021年开始任职公司董事，具备多年产业投资和企业经营管理经验。 新管理团队自上任以来，积极优化辽宁成大融资结构，控制资金成本，强化融资能力与融资韧 ...

本轮融资由领航新界资本领投。本轮所募资金将主要用于加速公司化学合成QS-21等佐剂原料的GMP生 产基地建设，推动在全球范围内的商业化进程，并进一步拓展公司在新型佐剂领域的研发管线。 11月21日，重庆百达信生物技术有限公司（以下简称"百达信生物"或"公司"）宣布已成功完成超过3000 万元人民币的Pre-A轮融资。 ...

经济观察网 据威斯克生物微信公众号消息，近日，由威斯克生物联合四川大学华西医院自主研发的痤 疮治疗性疫苗，正式获得中国国家药品监督管理局（NMPA）新药临床试验申请（IND）批准，成为我 国首款进入临床阶段的痤疮治疗性疫苗。威斯克生物是一家创新型生物医药企业，2021—2025年连续四 年成功入选独角兽企业，在北京、成都和广州设立了研发、生产和销售机构。 ...

大赛虽已收官，但创新创业的故事才刚刚启幕。从7146个项目中脱颖而出的优秀团队，正手握技术的利 刃，怀揣改变世界的热情，成为湾区建设中最具活力的"新星力量"。 为持续讲述这些动人的创新篇章，本系列报道推出专题《湾区创talk·一期一会》。以"一期一会"为主 线，我们将一次次走近大赛获奖项目，记录思想的碰撞、技术的迭代与梦想的生长——创业菁英们用人 工智能重塑生产力，以生物医药守护人类健康，借智能装备升级传统行业，凭文化创意点亮美好生活。 从院士领衔的尖端平台，到青年学子的奇思妙想；从意向融资过亿的"航母项目"，到扎根田野的智 能"农夫"……每一次相遇，都是对创新精神的致敬；每一次"一期一会"，都是湾区未来的注脚。 在刚刚落幕的2025年粤港澳大湾区创业大赛的舞台上，一个来自香港的艾滋病治疗性核酸疫苗项目脱颖 而出。医克生物行政总裁兼联合创始人金侠在进行了12分钟的路演与答疑后，项目不仅斩获大赛生物医 药赛道特等奖，更收获了四家投资机构总额8500万元的意向投资。 其中，意向出资最高的川商基金当场与团队签署投资意向书。两周之后，双方在上海进行了近4小时的 闭门会谈，继续深入了解。这一项目的独创性在哪里？从香港走 ...

开栏语：珠江潮起，湾区奔涌。当粤港澳大湾区从宏伟蓝图加速照进现实，这片热土已成为无数创业梦 想拔节生长的首选之地和理想之城。刚刚圆满落幕的2025年粤港澳大湾区创业大赛，不仅是一场高手云 集、精彩纷呈的竞技，更是一次创新力量与未来产业的集中巡礼。 大赛虽已收官，但创新创业的故事才刚刚启幕。从7146个项目中脱颖而出的优秀团队，正手握技术的利 刃，怀揣改变世界的热情，成为湾区建设中最具活力的"新星力量"。 为持续讲述这些动人的创新篇章，本系列报道推出专题《湾区创talk·一期一会》。以"一期一会"为主 线，我们将一次次走近大赛获奖项目，记录思想的碰撞、技术的迭代与梦想的生长——创业菁英们用人 工智能重塑生产力，以生物医药守护人类健康，借智能装备升级传统行业，凭文化创意点亮美好生活。 从院士领衔的尖端平台，到青年学子的奇思妙想；从意向融资过亿的"航母项目"，到扎根田野的智 能"农夫"……每一次相遇，都是对创新精神的致敬；每一次"一期一会"，都是湾区未来的注脚。 在刚刚落幕的2025年粤港澳大湾区创业大赛的舞台上，一个来自香港的艾滋病治疗性核酸疫苗项目脱颖 而出。医克生物行政总裁兼联合创始人金侠在进行了12分钟的路 ...

荷牧生物由国内先进的技术开发团队及实力强大的管理团队共同打造，是国内首家专注于动物新型 mRNA疫苗创新型研发企业。致力于新型动物病毒性传染病mRNA疫苗研发，通过不断的产品创新，提 供更安全更有效的新型疫苗。 同时开展精准的动物传染病体外检测试剂研发，建立全面完善的病原检 测及预防解决方案，为全国乃至世界的畜牧业健康发展提供保障。 | 公布日 | 投资方 | 交易金额 | 融资轮次 | | --- | --- | --- | --- | | 2025-11-02 | 中美绿色基金 | 未披露 | A轮 | | 2024-04-22 | 临空集团 | 未披露 | 股权融资 | | 2023-12-11 | 宽带智汇母基金 | 未披露 | Pre-A轮 | | 2022-12-13 | 依依股份 中美绿色真金 | 1550万人民币 | 天使+ | | | 个人投资者 | | | | | 英诺天使基金 | | | | 2022-10-20 | 泰有其余 | 未披露 | 天使轮 | | | 水木清华校友墓金 | | | 证券之星消息，根据天眼查APP于11月2日公布的信息整理，北京荷牧生物科技有限公司A轮融资，融 ...

Core Viewpoint - The report indicates that Beijing Kanglwei Biological Technology Co., Ltd. has shown significant revenue growth while still facing losses, marking a transition in its financial performance and business strategy [1] Financial Performance - As of the end of September, the company achieved total revenue of approximately 1.2763 million, representing a year-on-year increase of 106.53% [1] - The company reported a net loss of about 229 million, although this reflects a year-on-year reduction of 16.6% [1] - The net profit growth of 16.6% for the current quarter marks the first time in three years that the company has shifted from negative to positive growth in this metric [1] Business Overview - Founded in 2008, the company focuses on innovative vaccine research and industrialization, positioning itself as a high-tech enterprise [1] - It is recognized as a leader in HPV vaccine research in China, boasting the most comprehensive HPV vaccine product portfolio globally, including three-valent, nine-valent, and fifteen-valent vaccines [1] - The company transitioned from biopharmaceutical research to commercialization, indicating a strategic shift in its business model [1] Market Position - The company successfully listed on the Beijing Stock Exchange on March 15, 2023, under the fourth set of unprofitable standards, making it one of the few companies to do so [1] - It is also the first company to apply for dual listing on both the Beijing and Hong Kong stock exchanges [1]

Core Viewpoint - 百克生物 is committed to innovation-driven development in the booming global biopharmaceutical industry, with a well-structured and diverse research pipeline that enhances its competitive edge [1][2]. R&D Strategy - The company has established a tiered R&D strategy focusing on "upgrading, filling gaps, and innovative breakthroughs," creating a product matrix that addresses health needs across all demographics [1][3]. - The R&D model includes a "production generation, R&D generation, and reserve generation" approach, ensuring a comprehensive layout from mature product production to cutting-edge technology reserves [2]. Key Products and Pipeline - Core products in the "production generation" include varicella vaccine, nasal spray influenza vaccine (both freeze-dried and liquid forms), and attenuated live vaccine for herpes zoster, which support the company's growth [2]. - "R&D generation" products, such as acellular DTP vaccine and adjuvanted influenza vaccines, are currently in clinical stages, while "reserve generation" products like HSV-2 mRNA vaccine and Alzheimer's therapeutic vaccine lay the foundation for long-term development [2]. Technological Platforms - The company has developed five core technology platforms: virus large-scale culture, formulation and adjuvant technology, genetic engineering, bacterial vaccine technology, and mRNA vaccine technology, supporting 13 vaccine projects and 3 monoclonal antibodies for infectious disease prevention [3]. - The company has achieved breakthroughs in mRNA vaccines and recombinant protein vaccines, with proprietary adjuvants already applied in various vaccine formulations [3]. Recent Achievements - In the first ten months of the year, the company received one production license for liquid nasal spray influenza vaccine and submitted five clinical trial applications for adjuvanted influenza vaccines, with four already approved [3][4]. - The company is developing a multi-component HSV-2 mRNA vaccine that enhances immune response and has initiated Phase I clinical trials, which could significantly enrich its product pipeline [4]. - The Alzheimer's therapeutic vaccine is in preclinical research, showing promising safety and immunogenicity, with potential applications for early treatment and prevention in at-risk populations [4].

Core Viewpoint - The announcement details a strategic cooperation agreement between Liaoning Chengda Biological Co., Ltd. and the Institute of Microbiology, Chinese Academy of Sciences, focusing on the prevention of vector-borne infectious diseases and collaborative research projects [2][15]. Group 1: Agreement Overview - The strategic cooperation agreement is an intention-based collaboration aimed at addressing emerging infectious diseases, particularly vector-borne diseases [2][10]. - The agreement was signed on October 21, 2025, in Shenyang, Liaoning Province [5]. - The agreement does not require board or shareholder approval, as it is an intention-based agreement [7][8]. Group 2: Parties Involved - The Institute of Microbiology is a research institution with a registered capital of 63.23 million yuan, located in Beijing [4]. - There is no related party relationship between the Institute of Microbiology and Chengda Biological [4]. Group 3: Cooperation Details - The cooperation will focus on joint research projects, strategic consulting for disease prevention, and deep integration of industry and academia [10][11]. - A joint laboratory will be established to support the development of a key laboratory for synthetic immunology and vaccine manufacturing [11]. - Both parties will share knowledge and conduct training to enhance technological capabilities in the field of infectious disease prevention [11]. Group 4: Impact on Company - The collaboration is expected to integrate top resources from the Institute of Microbiology with the company's vaccine development platform, accelerating the research and development of vaccines and biopharmaceuticals [15]. - The partnership aligns with the company's long-term strategy to focus on vaccines and expand into the biopharmaceutical sector, laying a solid foundation for building a biopharmaceutical industry cluster [15]. - The agreement is not expected to have a direct impact on the company's performance in 2025, with specific effects dependent on future project developments [2][15].